Form 8-K - Current report:
SEC Accession No. 0001213900-24-087394
Filing Date
2024-10-15
Accepted
2024-10-15 06:03:19
Documents
16
Period of Report
2024-10-14
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0217519-8k_jasper.htm   iXBRL 8-K 29099
2 PRESS RELEASE, DATED OCTOBER 14, 2024 ea021751901ex99-1_jasper.htm EX-99.1 21934
3 GRAPHIC ex99-1_001.jpg GRAPHIC 6939
  Complete submission text file 0001213900-24-087394.txt   289245

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE jspr-20241014.xsd EX-101.SCH 3930
5 XBRL DEFINITION FILE jspr-20241014_def.xml EX-101.DEF 26836
6 XBRL LABEL FILE jspr-20241014_lab.xml EX-101.LAB 37099
7 XBRL PRESENTATION FILE jspr-20241014_pre.xml EX-101.PRE 25460
19 EXTRACTED XBRL INSTANCE DOCUMENT ea0217519-8k_jasper_htm.xml XML 5906
Mailing Address 2200 BRIDGE PKWY SUITE #102 REDWOOD CITY CA 94065
Business Address 2200 BRIDGE PKWY SUITE #102 REDWOOD CITY CA 94065 6505491400
Jasper Therapeutics, Inc. (Filer) CIK: 0001788028 (see all company filings)

EIN.: 842984849 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39138 | Film No.: 241368943
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)